Kura Oncology (KURA) Change in Accured Expenses (2010 - 2026)

Kura Oncology (KURA) has 14 years of Change in Accured Expenses data on file, last reported at -$16.2 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 88.25% year-over-year to -$16.2 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 55.45% decrease from a year earlier, with the FY2025 full-year figure at $12.7 million, down 24.8% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$16.2 million, down from -$2.2 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for KURA reached as high as $14.3 million in Q4 2024 and fell as low as -$16.2 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $1.4 million across 5 years, with a median of -$50000.0 in 2024.
• Across the five-year window, Change in Accured Expenses slumped 5132.26% in 2022 and surged 21524.0% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$1.6 million in 2022, then jumped by 649.36% to $8.6 million in 2023, then soared by 67.2% to $14.3 million in 2024, then slumped by 115.07% to -$2.2 million in 2025, then slumped by 650.74% to -$16.2 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$16.2 million in Q1 2026, -$2.2 million in Q4 2025, and $12.7 million in Q3 2025.